Risk factors and predictive biomarkers of immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer
10.3760/cma.j.cn371439-20210115-00057
- VernacularTitle:非小细胞肺癌免疫检查点抑制剂相关性肺炎的危险因素及预测生物标志物
- Author:
Hui WANG
;
Rong XIA
;
Qingwen WEI
;
Yixin WAN
- From:
Journal of International Oncology
2021;48(5):296-301
- CountryChina
- Language:Chinese
-
Abstract:
The use of immune checkpoint inhibitors (ICIs) has changed the clinical outcome of non-small cell lung cancer (NSCLC), with the widespread application of ICIs, immune-related adverse events (irAEs) have also appeared. Immune checkpoint inhibitor pneumonitis (CIP) is a serious adverse event of ICIs treatment that needs attention. Therefore, early identification of high-risk groups of CIPs and early intervention can reduce the occurrence of permanent drug withdrawal and severe CIPs, thereby improving patients′ prognosis.
